Current Illinois CancerCare Clinical Trals

Follicular Lymphoma


M22-003

Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants with Previously Untreated Follicular Lymphoma (EPCORE™FL-2)


S2308

RANDOMIZED PHASE III STUDY OF MOSUNETUZUMAB VS. RITUXIMAB FOR LOW TUMOR BURDEN FOLLICULAR LYMPHOMA


Search Again